A Phase 3 interventional study of JS002 and Placebo in Hyperlipemia, sponsored by Shanghai Junshi Bioscience Co., Ltd.. Completed at 57 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-04-19.
Sponsored by Shanghai Junshi Bioscience Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 96 studies in Hyperlipidemias with a site in China — 31 open to participants now, 39 under way, 7 of them phase 3. Hyperlipidemias · China.
Among the 96 studies in Hyperlipidemias with a site in China, this one is the 10th largest by enrollment of the 80 interventional ones that give a count, is one of 9 that started in 2020, is one of 20 in phase 3, and was the 31st registered.
864 studies on the registry are indexed under Hyperlipidemias; 110 are open to participants now.
Browse Hyperlipidemias studies →31 of the 96 studies in Hyperlipidemias with a site in China are open now. Recruiting first, the newest first:
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–79
Jianyin Zhou · Sites in China
Ages 18–65
Beijing Suncadia Pharmaceuticals Co., Ltd · Sites in China
Ages 18+
Shanghai 10th People's Hospital · Sites in China
Ages 18–60
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 66 Hyperlipidemias studies recruiting now, 26 (39%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
96 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 13 · Phase 3 20 · Phase 4 7
First in 2005; this study’s year is marked. 9 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 806 is above the median of 88 across 737 interventional studies indexed under Hyperlipidemias.
Median enrollment 155 across the 80 interventional studies, 1,151 across the 16 observational. Of the 44 that completed or were terminated, 4 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 96 have an industry lead sponsor. The 10 most frequent:
Shanghai Junshi Bioscience Co., Ltd. is the lead sponsor of 100 studies on the registry; 20 are open to participants now.
Shanghai Junshi Bioscience Co., Ltd. has 5 studies filed under Hyperlipidemias — fewer than ten, so there is no comparison to draw.
11 of the studies in Hyperlipidemias with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-01-16 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07230730Phase 3Beijing Suncadia Pharmaceuticals Co., LtdA Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia | 2027-10 |
| NCT05457582Nanjing First Hospital, Nanjing Medical UniversityPCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI | 2026-12-30 |
| NCT07938099Xin LiReal-World Study Comparing PCSK9 Monoclonal Antibody With Cholesterol Absorption Inhibitors in Patients With ASCVD for Secondary Prevention | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 96 studies in Hyperlipidemias with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody. This is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy, as well as immunogenicity of JS002 treated repeatedly in patients with hyperlipidemia when combined with statin therapy.
In this study, two dose group (150 mg, 300 mg) were set up in this study. 750 subjects are plan to be enrolled (the study drug will be assigned to a 2:1 ratio of JS002 or placebo).
Each subject required a maximum of 6 weeks of screening, 52 weeks of treatment, and 8 weeks of follow-up.
A limited list of criteria for selection of participants in the clinical study, provided in terms of inclusion and exclusion criteria and suitable for assisting potential participants in identifying clinical studies of interest. Use a bulleted list for each criterion below the headers "Inclusion Criteria" and "Exclusion Criteria". (Limit: 15,000 characters.) Inclusion criteria
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1: 150 mg/1mL Q2W Subcutaneous(SC); Cohort 2: 300/2mL mg Q4W Subcutaneous(SC);
Drug: JS002
Cohort 1: 1mL Q2W Subcutaneous(SC); Cohort 2: 2mL Q4W Subcutaneous(SC);
Drug: Placebo
JS002: 150mg(1mL) Q2W; Placebo 1mL Q2W.
JS002: 300mg(2mL) Q4W; Placebo 2mL Q4W.
Change in LDL-C of JS002
Percentage change in LDL-C relative to baseline at Week 24
Time frame: Up to 24Weeks after dose administration
Change in LDL-C of JS002
Percentage change in LDL-C relative to baseline at Week 52
Time frame: Up to 52Weeks after dose administration
Other lipid parameters of JS002
Percentage change in LDL-C relative to baseline at Week 24 and Week 52
Time frame: Up to Week 24 and 52Weeks after dose administration
The occurrence of adverse events
Evaluate the change of clinically significant laboratory tests, vital signs, and electrocardiogram
Time frame: Up 60Weeks after dose administration
The immunogenicity of JS002
To evaluate the production time, duration and proportion of anti JS002 antibody (ADA).ADA positive samples are tested for titer and for neutralizing antibody (Nab).
Time frame: Up 60Weeks after dose administration
Pharmacokinetics (PK) of JS002
Evaluation of Serum concentration of JS002.Descriptive statistics include mean (arithmetic mean and geometric mean), standard deviation (SD), coefficient of variation CV% (arithmetic coefficient and geometric coefficient of variation), Median (Median), minimum (Min) and maximum (Max).
Time frame: Up 60Weeks after dose administration
Pharmacokinetics (PD) of JS002
Evaluation of serum concentrations of free/total PCSK9 and changes from baseline.Descriptive statistics include mean (arithmetic mean and geometric mean), standard deviation (SD), coefficient of variation CV% (arithmetic coefficient and geometric coefficient of variation), Median (Median), minimum (Min) and maximum (Max).
Time frame: Up 60Weeks after dose administration
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2020 to primary completion in May 2022, 17 months.
Of 57 phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 32. This study's 17 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ongericimab
Shanghai Junshi Bioscience Co., Ltd. →